

C2 34. (Twice Amended) The adenovirus according to claim 27, wherein the [DNA] cDNA sequence is placed under [the] control of a signal controlling expression in a target [cells] cell.

C3 36. (Twice Amended) The adenovirus according to claim 35, wherein the viral promoter is selected from the group consisting of E1A, MLP, CMV, and RSV-LTR promoters.

C4 38. (Twice Amended) The adenovirus according to claim 27, [comprising a genomic DNA or] wherein the cDNA sequence [encoding a human glutathione peroxidase] is placed under [the] control of an RSV-LTR promoter.

C5 40. (Twice Amended) The adenovirus according to claim [39] 27, comprising ITRs and a sequence permitting encapsidation, and wherein [the] an adenoviral E1 gene and at least one of [the] an adenoviral E2, E4, or L1-L5 genes are not functional.

41. (Twice Amended) The adenovirus according to claim [39] 27, wherein said adenovirus is an Ad 2 or Ad 5 human adenovirus or a CAV-2 canine adenovirus.

C6 48. (Amended) A cultured mammalian cell infected with [one or more] the replication defective recombinant [adenoviruses] adenovirus according to claim 27.

#### REMARKS

Claims 27, 34-36, 38, 40, 41, and 48-50 are pending in this application. Claims 28-33, 37, 44-47, and 51-55 have been canceled without prejudice, solely in an effort to advance prosecution. Applicants reserve the right to pursue the subject matter of the cancelled claims in divisional and continuation applications.

Claims 27, 34, 36, 38, 40, 41, and 48 have been amended to more particularly point out and distinctly claim that which Applicants regard as their invention. Support for these amendments may be found in the claims as originally filed and in the specification. Support for amended claim 48 is found on page 13, line 15 to page 14, line 24 of the specification. No new matter has been added. Entry of the instant amendment is respectfully requested. For the Examiner's convenience, a copy of the pending claims, as amended, is attached hereto as an APPENDIX.